Sumitomo Pharma America Unveils First Clinical Findings for Investigational CHK1 Inhibitor SMP-3124LP at ASCO 2026

Sumitomo Pharma America Reports Promising Early Clinical Results for Investigational CHK1 Inhibitor SMP-3124LP in Advanced Solid Tumors Sumitomo Pharma America, Inc. (SMPA) has unveiled encouraging clinical findings from its ongoing…

Read MoreSumitomo Pharma America Unveils First Clinical Findings for Investigational CHK1 Inhibitor SMP-3124LP at ASCO 2026

FDA Approves FoundationOne CDx Tests as Companion Diagnostics for TALZENNA + XTANDI in HRR-Mutated mCRPC

FDA Approves FoundationOne CDx Tests as Companion Diagnostics for TALZENNA and XTANDI in HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer Foundation Medicine, a global precision medicine company dedicated to advancing personalized…

Read MoreFDA Approves FoundationOne CDx Tests as Companion Diagnostics for TALZENNA + XTANDI in HRR-Mutated mCRPC

Lysoway Therapeutics Secures Michael J. Fox Foundation Grant to Advance Parkinson’s Disease Therapy

Lysoway Therapeutics Secures Additional MJFF Funding to Advance TMEM175 Agonist Program for Parkinson’s Disease Lysoway Therapeutics, a biopharmaceutical company focused on developing small-molecule therapies that target lysosomal ion channels, has…

Read MoreLysoway Therapeutics Secures Michael J. Fox Foundation Grant to Advance Parkinson’s Disease Therapy

Corcept Therapeutics Shows Lifyorli Overall Survival Benefit in Platinum-Resistant Ovarian Cancer at ASCO 2026

Corcept Therapeutics Reports Statistically Significant Overall Survival Benefit for Lifyorli in Platinum-Resistant Ovarian Cancer at ASCO 2026 Corcept Therapeutics Incorporated, a commercial-stage biopharmaceutical company focused on discovering and developing therapies…

Read MoreCorcept Therapeutics Shows Lifyorli Overall Survival Benefit in Platinum-Resistant Ovarian Cancer at ASCO 2026

PanTher Completes Phase 1b Dose Escalation in Non-Metastatic Pancreatic Cancer and Appoints Tim Clackson to Board of Directors

PanTher Therapeutics Advances PTM-101 with Phase 1b Dose Escalation Completion in Pancreatic Cancer and Appoints Oncology Veteran Tim Clackson to Board PanTher Therapeutics, a clinical-stage biotechnology company developing implant-based localized…

Read MorePanTher Completes Phase 1b Dose Escalation in Non-Metastatic Pancreatic Cancer and Appoints Tim Clackson to Board of Directors

Canopy Growth Reintroduces Tweed Brand in Germany with New MTL Cannabis Lineup, First Post-Acquisition Global Launch

Canopy Growth Relaunches Tweed Brand in Germany and Expands Medical Cannabis Portfolio Following MTL Acquisition Canopy Growth Corporation has announced a major strategic milestone in its international expansion strategy with…

Read MoreCanopy Growth Reintroduces Tweed Brand in Germany with New MTL Cannabis Lineup, First Post-Acquisition Global Launch